Home/Pipeline/BK-508 (Dual-specific Antibody)

BK-508 (Dual-specific Antibody)

Advanced Solid Tumors

Phase I/IIRecruiting

Key Facts

Indication
Advanced Solid Tumors
Phase
Phase I/II
Status
Recruiting
Company

About Sichuan Biokin Pharmaceutical

Sichuan Biokin Pharmaceutical's mission is to develop and commercialize high-quality, accessible biologic medicines for patients in China and worldwide. The company has achieved significant success by establishing itself as a dominant player in the Chinese biologics market, evidenced by its substantial market capitalization and integrated capabilities from discovery through commercialization. Its core strategy employs a dual-track approach: generating stable cash flow from biosimilars to fund the research and development of novel therapeutic antibodies in high-value therapeutic areas.

View full company profile

Therapeutic Areas

Other Advanced Solid Tumors Drugs

DrugCompanyPhase
NT219Purple BiotechPhase 1/2
INDP-101Indaptus TherapeuticsPhase 1
PM14PharmaMarPhase 1/2
Ecubectedin (PM54)PharmaMarPhase 1
AP-202Advance PharmaceuticalPhase 1/2
BI-1808BioInvent InternationalPhase 1/2a
GIGA-564GigaGenPhase 1
Venadaparib (IDX-1197)IdiencePhase 1a
VET3-TGIKaliVir ImmunotherapeuticsPhase 1
IT-141 (Etoposide IVECT™)IntezynePhase 1
NC318NextCurePhase 1/2
VisAcT (18F-AraG) Imaging in Solid TumorsCellSight TechnologiesPhase 1/2